Nexvet's Q4 loss doubles; ARTES strikes vaccine deal with Boehringer; Tyson ditches human antibiotics in chicken production;

> Newly public Nexvet ($NVET) announced that its net loss in the fourth quarter of 2014 doubled year over year to $2.4 million and that its current cash store is $21.7 million. Release

> ARTES Biotechnology and Boehringer Ingelheim Animal Health announced a collaboration to develop vaccines for veterinary use. Release

> Tyson Foods is no longer using gentamicin, an antibiotic used to treat human disease, in its chicken production. Article

> The International Federation for Animal Health has named George Heidgerken to a two-year term as president. Release

> Traverse Biosciences has formed a license agreement with the Research Foundation for the State University of New York to develop a product to treat periodontal disease in dogs. Release

> The FDA has issued a draft guidance for animal producers to better identify and prevent feed contaminants that could threaten the health of farm animals. Release

> Galileo Diagnostics has been appointed international veterinary distributor for D-Eye's Portable Retinal Imaging System. Release

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…